



PREVALENCE OF HELICOBACTER PYLORI IN DIFFERENT SURGICAL DISEASES: A PRELIMINARY REPORT

Mirka Ilic¹, Nada Popovic²

1. Center for Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia
2. Department of Anesthesiology and Emergency Surgery, Medical School of Belgrade-University of Belgrade & Clinical Center of Serbia, Belgrade, Serbia

Corresponding author's address

Mirka Ilic, PhD
Center for Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia
Visegradska 26, 11000 Belgrade, Serbia.
Tel/fax: +381 11 3615631
E-mail: m_ilic@beotel.net

ABSTRACT

The aim of this study was to explore the prevalence of Helicobacter pylori infection in different surgical diseases in patients with six different cancer types. We analyzed sixty consecutive patients with malignancy (gastric cancer, pancreatic cancer, hepatocellular cancer, intestinal cancer, colon cancer, rectal cancer). Detection of specific IgA and IgG antibodies to Helicobacter pylori in human serum was determined by Enzygnost Anti-Helicobacter pylori II/IgA (IgG) using ELISA processor (Siemens, Germany). This study confirmed statistically significant association between Helicobacter pylori seropositivity and all types of cancer included in the study. All patients had elevated levels of Helicobacter pylori IgA and IgG antibodies. Patients with examined cancer types that underwent abdominal surgery exhibited a strong antibody reaction to Helicobacter pylori.

INTRODUCTION

Helicobacter pylori is the commonest chronic infection in humans. About half of the population in the developed countries carries this bacteria and nearly 90% are adults (1). The prevalence of H. pylori varies widely. More than 80% of adults are infected in Japan and South America (2). In European countries 30-60% of middle aged has serological evidence of infection (3). Epidemiological evidence suggests that many people acquire the infection in childhood. Social deprivation household crowding and number of siblings are the important risk factors. The prevalence of infection increases with age, although this may be largely a cohort effect (4). The mode of transmission is unknown but proposed routes include oral-oral and faecal-oral. Helicobacter pylori have been implicated as having a pathological role in a variety of gastrointestinal diseases. The International Agency for Research on cancer has categorized Helicobacter pylori as a group I carcinogen (5). Small number of studies confirmed H. pylori as an important factor linked to the development of malignancy.

The aim of this study was to explore the prevalence of H. pylori infection in different surgical diseases in patients with six different cancer types.

PATIENTS, MATERIALS AND METHODS

This study reports preliminary results of the large prospective, cohort study carried out in the Clinical Center of Serbia. We analyzed 60 consecutive patients with malignancy (gastric cancer, pancreatic cancer, hepatocellular cancer, intestinal cancer, colon cancer, rectal cancer) who underwent surgical treatment at the Department of Emergency Surgery of Clinical Centre of Serbia, between September 2007 and September 2009. Patient data consisted of age, gender, diagnosis and Helicobacter pylori status. Preoperative evaluation was done in all patients. In each group we analyzed the presence H. pylori infection. The blood samples were taken for testing Helicobacter pylori prior to surgery. Commercial test Enzygnost Anti-Helicobacter pylori II/IgA (IgG) (Simens, Germany) was used for the qualitative detection of H. pylori -specific human IgA and IgG antibodies in the serum. Quantification in Enzygnost-units (U/mL) is achieved by a single-point procedure.

STATISTICAL ANALYSIS

Data were presented as mean \pm standard deviations or as percentages of total values. Difference was considered statistically significant if p value was less than 0.05. All the available data were analyzed by computer program (SPSS, Chicago, IL, USA).

RESULTS

Mean age in all patients groups was 60 ± 12 years. The study included 36 men and 24 women. The prevalences of specific IgA and IgG antibodies to Helicobacter pylori in patient's serum according to cancer type are given in Table 1. The most frequent cancer type were rectal and hepatocellular. All patients, regardless the cancer type, had elevated H. pylori IgA and IgG antibodies levels.

Table1. Prevalence of Helicobacter pylori in different types of cancer

Cancer type	Number of patients (%)	IgG positive	IgA positive
Gastric cancer	6 (10.0%)	6	6
Pancreatic cancer	8 (13.3%)	8	8
Hepatocellular cancer	14 (23.3%)	14	14
Intestinal cancer	7 (11.7%)	7	7
Colon cancer	11 (18.3%)	11	11
Rectal cancer	14 (23.4%)	14	14

DISCUSSION

The main finding of this study was that patients with examined cancer types that underwent abdominal surgery exhibited a strong antibody reaction to Helicobacter pylori. All of them were positive of H. pylori infection.

H. pylori has been implicated as a carcinogenic factor for non-cardia gastric cancer and causes a persistent inflammatory-proliferative state that evolves from chronic superficial gastritis to precancerous atrophic gastritis, metaplasia, and dysplasia (6). Prospective epidemiological studies have shown that H. pylori positive patients may be indicated in high risk populations of non-cardia gastric cancer development (7,8). Most studies of Asian populations have found a positive association between H. pylori seropositivity and cardia cancer, whereas most studies of Western

populations have found no association or an inverse association (8, 9). Meta-analysis of Huand and coworkers confirmed the relationship between *H. pylori* seropositivity and gastric cancer (10).

Pancreatic cancer is among the most fatal cancers worldwide and one for which few preventable risk factors has been established. Gastric carriage of *H. pylori*, particularly cytotoxin-associated gene-A-positive (*CagA*+) strains, is a risk factor for peptic ulcer disease and gastric cancer and may have a similar etiologic relationship with pancreatic cancer. Two previously published studies (11,12) examined *H. pylori* and pancreatic cancer. The first study found greater *H. pylori* seropositivity among 92 subjects with pancreatic cancer (65%) than among 62 control subjects (45%; control subjects had either colorectal cancer or no disease) and showed a similar significant doubling of risk. The other study of Stolzenberg-Solomon and coworkers supported a possible role for *H. pylori* carriage in the development of exocrine pancreatic cancer.

However, the possibility that *Helicobacter pylori* is an initiator of colorectal neoplasia (13, 14) is a subject of debate. Most associations between neoplastic colorectal lesions (adenomas and carcinomas) and *H. pylori* are based on studies correlating these lesions with *H. pylori* seropositivity (15-18) or indirect evidence such as increased gastrin or *CagA*+ levels (19,20). Other studies have failed to demonstrate this association based on seropositivity (21-23); indeed it has been suggested that *H. pylori* does not colonize rectal mucosa (24).

Although our preliminary results suggests the association of *H. pylori* positivity and different cancers, further studies are necessary.

Bibliography

1. Lin MH, Chen LK, Hwang SJ, Lee SC, Wu TC. Childhood functional abdominal pain and *Helicobacter pylori* infection. *Hepatogastroenterology* 2006; 53:883-6.
2. Malaty HM. Epidemiology of *Helicobacter pylori* infection. *Best Pract Res Clin Gastroenterol.* 2007;21:205-14
3. Poullis A, Poullis M. *Helicobacter pylori* and cardiac surgery. *Eur J Cardiothorac Surg* 2001;20:217-8.
4. Fuccio L, Laterza L, Zagari RM, Cennamo V, Grilli D, Bazzoli F. Treatment of *Helicobacter pylori* infection. *BMJ* 2008;337:a1454.
5. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA* 2004;291:187-94.
6. Forman D. *Helicobacter pylori* infection and cancer. *Br Med Bull* 1998;54:71-8.
7. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007;56:772-81.
8. *Helicobacter and Cancer Collaborative Group*. Gastric cancer and *Helicobacter pylori*: a combined analysis of 12 case control studies nested within prospective cohorts. *Gut* 2001;49:347-53.
9. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with *Helicobacter pylori* seropositivity. *J Natl Cancer Inst* 2006;98:1445-52.
10. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between *Helicobacter pylori* seropositivity and gastric cancer. *Gastroenterology* 1998;114:1169-79.
11. Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G, Hejna M, Scheithauer W. Association between *Helicobacter pylori* infection and pancreatic cancer. *Oncology* 1998;55:16-9.
12. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, Albanes D; ATBC Study. *Helicobacter pylori* seropositivity as a risk factor for pancreatic cancer. *J Natl Cancer Inst* 2001;93:937-41.
13. Konturek SJ, Konturek PC, Hartwich A, Hahn EG. *Helicobacter pylori* infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies. *Regul Pept* 2000;93:13-9.
14. Meucci G, Tatarella M, Vecchi M, Ranzi ML, Biguzzi E, Beccari G, Clerici E, de Franchis R. High prevalence of *Helicobacter pylori* infection in patients with colonic adenomas and carcinomas. *J Clin Gastroenterol*

- 1997;25:605-7.
15. Aydin A, Karasu Z, Zeytinoglu A, Kumanlioglu K, Ozacar T. Colorectal adenomatous polyps and Helicobacter pylori infection. *Am J Gastroenterol.* 1999;94:1121-2.
 16. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H. Helicobacter pylori and the risk of colonic adenomas. *Colorectal Adenoma Study Group. Digestion* 1999;60:210-5.
 17. Fireman Z, Trost L, Kopelman Y, Segal A, Sternberg A. Helicobacter pylori: seroprevalence and colorectal cancer. *Isr Med Assoc J* 2000;2:6-9.
 18. Fujimori S, Kishida T, Kobayashi T, Sekita Y, Seo T, Nagata K, Tatsuguchi A, Gudis K, Yokoi K, Tanaka N, Yamashita K, Tajiri T, Ohaki Y, Sakamoto C. Helicobacter pylori infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women. *J Gastroenterol* 2005;40:887-93.
 19. Hartwich J, Konturek SJ, Pierzchalski P, Zuchowicz M, Konturek PC, Bielanski W, Marlicz K, Starzynska T, Lawniczak M. Molecular basis of colorectal cancer-role of gastrin and cyclooxygenase-2. *Med Sci Monit* 2001;7:1171-81.
 20. Konturek PC, Bielanski W, Konturek SJ, Hartwich A, Pierzchalski P, Gonciarz M, Marlicz K, Starzynska T, Zuchowicz M, Darasz Z, Gotze JP, Rehfeld JF, Hahn EG. Progastrin and cyclooxygenase-2 in colorectal cancer. *Dig Dis Sci* 2002;47:1984-91.
 21. Limburg PJ, Stolzenberg-Solomon RZ, Colbert LH, Perez-Perez GI, Blaser MJ, Taylor PR, Virtamo J, Albanes D. Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers. *Cancer Epidemiol Biomarkers Prev* 2002;11:1095-9.
 22. Moss SF, Neugut AI, Garbowski GC, Wang S, Treat MR, Forde KA. Helicobacter pylori seroprevalence and colorectal neoplasia: evidence against an association. *J Natl Cancer Inst* 1995;87:762-3.
 23. Siddheshwar RK, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of Helicobacter pylori in patients with colorectal polyps and colorectal carcinoma. *Am J Gastroenterol* 2001;96:84-8.
 24. Lizza F, Maletta M, Imeneo M, Monteleone G, Marasco R, Biancone L, Pallone F. Evidence against colonic mucosa colonisation by Helicobacter pylori. Lack of a specific antibody response in homogenates of rectal endoscopic biopsies. *Ital J Gastroenterol* 1996;28:447-51.